NICE chuan a vawi khat nan damdawi thar siam a rawt a, hei hian naute, naupang leh thalai cancer enkawl mekte chu hriatna hloh lo tura pui thei tur a ni.
Cisplatin hi chemotherapy damdawi chak tak a ni a, naupang cancer chi hrang hrang enkawlna atana hman lar tak a ni. Hun kal zelah cisplatin hi beng chhungah a pungkhawm thei a, ototoxicity tia hriat, hriatna hloh chhan pakhat a ni a, inflammation leh damage a thlen thei a ni.
Final draft recommendation-ah chuan naupang thla 1 atanga kum 17 inkar, solid tumor nei, taksa hmun danga darh lote chu cisplatin chemotherapy avanga hriatna hloh lo turin anhydrous sodium thiosulfate, Pedmarqsi tia hriat bawk leh Norgine siam hman a rawt a ni.
Cisplatin hmanga enkawl naupang 60% vel chuan hriatna hloh nghet an nei dawn a, kum 2022 leh 2023 inkar khan England-ah naupang kum 18 hnuai lam zingah ototoxic hearing loss vei thar 283 hmuhchhuah a ni.
Nurse emaw doctor emaw infusion anga pek damdawi hian cell-in a lak loh cisplatin nena inzawmin a hnathawh a tikhawlo a, chu chuan beng cell tihchhiat a veng thei a ni. Sodium thiosulfate anhydrous hman hian cisplatin chemotherapy hman tangkai dan a nghawng lo.
Anhydrous sodium thiosulfate hman tura rawtna siam kum khatnaah England rama naupang leh thalai maktaduai 60 velin he damdawi hi an dawng thei dawn niin an chhut.
Cancer enkawlna avanga hriatna hloh hian naupang leh an chhungte chungah nghawng tha lo tak a nei thei a, chuvangin he enkawlna kawng thar hi kan rawn rawt thei hi kan lawm hle.
Hei hi hriatna hloh avanga nghawng a veng leh tihziaawmna damdawi finfiah hmasak ber a ni a, naupang leh thalai nunah nghawng nasa tak a nei dawn a ni.
Helen-i chuan heti hian a sawi chhunzawm a: “He enkawlna thar kan rawtna hian NICE-in thil pawimawh ber: damlote hnena enkawlna ṭha ber pek thuai leh chhiah petu tâna sum hlutna ṭha tak neih theihna tura ngaihtuahna sen a tumzia a târ lang a ni,” a ti.
Clinical trial pahnih data atanga a lan dan chuan he enkawlna hian naupang cisplatin chemotherapy dawngte hriatna hloh zat chu a chanve vel zetin a ti tlem a ni. Clinical trial pakhatah chuan naupang cisplatin chemotherapy dawng a, chu chu anhydrous sodium thiosulfate pek a ni a, chu chu 32.7% zetin an hre thei a, cisplatin chemotherapy chauh dawng naupangte chu 63% zetin an hre thei lo tih hmuhchhuah a ni.
Zirchianna dang pakhatah chuan cisplatin chauh dawng naupang 56.4% chuan hriatna hloh an nei a, cisplatin dawng zinga 28.6% chuan anhydrous sodium thiosulfate an dawng thung.
Trial-ah hian naupangte hian hriatna hloh an nei tak tak a nih chuan anhydrous sodium thiosulfate hmangtute zingah a tlangpuiin a na lo zawk tih a tarlang bawk.
Nu leh pate chuan independent NICE committee hnenah cisplatin chemotherapy avanga hriatna hloh a nih chuan thusawi leh tawng hmasawnna bakah sikul leh in lama hnathawhnaah nghawng a nei thei tih an sawi.
He damdawi groundbreaking hi cancer enkawl mek naupangte tan cisplatin chemotherapy side effect anga hriatna hloh loh nan hman a ni dawn tih kan puang thei hi kan lawm hle a ni.
Ralph chuan, “He damdawi hi ram puma damdawi-inah hmuh kan nghakhlel hle a, naupang a hlawkpui thei zawng zawngte chuan he nunna chhanhimna damdawi hi an dawng thuai ngei kan beisei. Kan thlawptute chungah lawmthu kan sawi a, hei hian RNID-in NICE-in UK ram pumah he damdawi hi zau taka hman theih tura pui turin ngaihtuahna pawimawh leh finfiahna a pe thei a ni. Hei hi a vawi khatna atan damdawi hi hriatna hloh lohna tur venna atana a bik taka siam a ni a, a ni recommended for use on the NHS. Hei hi thil pawimawh tak a ni a, chu chuan hriatna hloh enkawlna lama sum dah leh siamtute chu damdawi pakhat chu hlawhtling takin market-ah an rawn chhuah thei tih rinna a pe ang.”.
NICE kaihhruaina hnuhnung ber tihchhuah a nih aṭanga thla thum chhungin England-a NHS-ah enkawlna hi hman theih a ni ang.
Company hian National Health Service hnenah anhydrous sodium thiosulfate man tlawm zawka supply turin confidential commercial agreement an siam a ni.